FAQ on Kairos Pharma Ltd.'s DoD Grant and Lung Cancer Biomarker Research

What is Kairos Pharma Ltd. focusing on with the DoD grant?

Kairos Pharma Ltd. is focusing on advancing lung cancer biomarker research with the DoD grant, as part of its broader efforts in oncology therapeutics, including clinical trials for ENV105 and development of KROS101.

What are the key clinical trials Kairos Pharma is currently advancing?

Kairos Pharma is advancing two clinical trials for its lead candidate ENV105 in prostate and EGFR-dependent non-small cell lung cancers, with safety and interim efficacy results expected in Q2 2025.

What is ENV105 and how does it work?

ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments, aiming to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.

Where can I find more information about Kairos Pharma Ltd.?

More information about Kairos Pharma Ltd. can be found on the company’s website at www.KairosPharma.com and in the company’s newsroom at https://ibn.fm/KAPA.

What is the significance of Kairos Pharma’s financial position and IP portfolio?

Kairos Pharma’s strong financial position and robust IP portfolio, extending into the 2030s, support its ongoing and future research and development efforts in oncology therapeutics, including non-dilutive government grants and expanding trial networks.

Who is the CEO of Kairos Pharma Ltd.?

The CEO of Kairos Pharma Ltd. is John Yu, M.D., who recently issued a shareholder letter outlining the company’s recent progress and strategic developments.

What is KROS101 and what recent developments have been made?

KROS101 is an immune response modulator being developed by Kairos Pharma, with recent data presented at key oncology conferences, indicating progress in its development.

When are the results from the ENV105 clinical trials expected?

Safety and interim efficacy results from the ENV105 clinical trials are expected in Q2 2025.

How does Kairos Pharma’s research address unmet medical needs?

Kairos Pharma’s research, particularly its clinical trials for ENV105 in castrate resistant prostate cancer and lung cancer, aims to address significant unmet medical needs by overcoming drug resistance and immune suppression in cancer.